RHO6 Stock Chart & Stats
€47.10
€2.45(5.49%)
At close: 4:00 PM EDT
€47.10
€2.45(5.49%)
Day’s Range― - ―
52-Week Range€32.33 - €50.95
Previous CloseN/A
Volume0.00
Average Volume (3M)15.00
Market Cap
€302.48B
Enterprise Value€363.86K
Total Cash (Recent Filing)€9.70B
Total Debt (Recent Filing)€31.69B
Price to Earnings (P/E)23.0
Beta0.54
Next Earnings
Feb 04, 2027EPS Estimate
1.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.94
Shares Outstanding5,620,501,500
10 Day Avg. Volume31
30 Day Avg. Volume15
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)7.76
Price to Sales (P/S)4.15
P/FCF Ratio19.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€48.35Price Target Upside2.65% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)2.69
Revenue Forecast (FY)€67.26B
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsEarly trontinemab data shows competitive amyloid clearance and improved ARIA rate versus peers, but clinical outcomes will determine success.
Financial PerformanceRoche's model was updated and numbers raised post recent business trends, with sales and EPS growth estimates increased.
Product EfficacyGazyva showed potential best-in-class profile in lupus nephritis and is likely to be the starter therapy of choice versus GSK's Benlysta.
Bears Say
Clinical Trial SafetyThere was a case of fatal cerebral macrohemorrhage in Part 2, leading to updated trial criteria to exclude patients with superficial siderosis.
Placebo ResponseThe high placebo response rate in males was notable, where placebo achieved a 66.7% complete renal response compared to 42.9% for Gazyva.
Roche Holding News
RHO6 FAQ
What was Roche Holding’s price range in the past 12 months?
Roche Holding lowest stock price was €32.33 and its highest was €50.95 in the past 12 months.
What is Roche Holding’s market cap?
Roche Holding’s market cap is €302.48B.
When is Roche Holding’s upcoming earnings report date?
Roche Holding’s upcoming earnings report date is Feb 04, 2027 which is in 186 days.
How were Roche Holding’s earnings last quarter?
Roche Holding released its earnings results on Jul 23, 2026. The company reported €1.443 earnings per share for the quarter, beating the consensus estimate of €1.391 by €0.052.
Is Roche Holding overvalued?
According to Wall Street analysts Roche Holding’s price is currently Undervalued.
Does Roche Holding pay dividends?
Roche Holding does not currently pay dividends.
What is Roche Holding’s EPS estimate?
Roche Holding’s EPS estimate is 1.29.
How many shares outstanding does Roche Holding have?
Roche Holding has 5,620,501,500 shares outstanding.
What happened to Roche Holding’s price movement after its last earnings report?
Roche Holding reported an EPS of €1.443 in its last earnings report, beating expectations of €1.391. Following the earnings report the stock price went up 0.597%.
Which hedge fund is a major shareholder of Roche Holding?
Currently, no hedge funds are holding shares in DE:RHO6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Roche Holding Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€48.35 (2.65% Upside)
€48.35 (2.65% Upside)
Blogger Sentiment
Bullish
DE:RHO6 Sentiment 75%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.59%
12-Months-Change
Fundamentals
Return on Equity
2.87%
Trailing 12-Months
Asset Growth
2.26%
Trailing 12-Months
Company Description
Roche Holding
Roche Holding AG functions as a major global healthcare enterprise, primarily concentrating its efforts within the pharmaceutical and diagnostic sectors. The company boasts an extensive international presence, with key operations located in countries such as Switzerland, Germany, the United States, Austria, the Netherlands, the United Kingdom, France, and Belgium. Its pharmaceutical division is dedicated to creating and supplying a diverse array of therapeutic remedies. These target a broad spectrum of medical fields, including oncology, neuroscience, immunology, cardiovascular and metabolic disorders, ophthalmology, and respiratory ailments. The comprehensive product line further extends to treatments for specific conditions like infectious diseases, anemia, various dermatological issues, hemophilia, inflammatory and autoimmune disorders, neurological conditions, and transplantation-related needs. Within its diagnostics segment, Roche develops and markets a wide variety of laboratory-based tests designed to identify and monitor numerous illnesses. These include, but are not limited to, cancer, diabetes, Covid-19, hepatitis, and human papillomavirus. Additionally, the company is a provider of essential diagnostic instruments and reagents. Established in 1896, Roche Holding AG maintains its corporate headquarters in Basel, Switzerland.
RHO6 Company Deck
RHO6 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed a positive operating and pipeline momentum despite identifiable headwinds. Roche reported strong profitability (core op profit +10%, margin expansion), solid organic growth in Pharma, multiple regulatory wins (5 priority reviews) and major diagnostics and R&D milestones (AXELIOS launch, CE marks, strategic M&A). Offsetting items include China pricing reform and a weak respiratory season hitting Diagnostics, currency translation pressures, a near‑term net debt increase (timing effects) and some competitive/biosimilar pressure in specific franchises. On balance, the operational and pipeline achievements materially outweigh the manageable challenges described.View all DE:RHO6 earnings summariesRHO6 Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€48.35
▲(2.65% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month











